Ernexa Therapeutics Inc.
ERNA
$0.2037
-$0.0043-2.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00K | 487.00K | 47.00K | 47.00K | 17.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00K | 487.00K | 47.00K | 47.00K | 17.00K |
| Cost of Revenue | 0.00 | -60.00K | 95.00K | 61.00K | 66.00K |
| Gross Profit | 1.00K | 547.00K | -48.00K | -14.00K | -49.00K |
| SG&A Expenses | 1.73M | 3.38M | 3.90M | 4.32M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70M | 4.32M | 4.98M | 5.83M | 5.78M |
| Operating Income | -2.70M | -3.84M | -4.93M | -5.79M | -5.77M |
| Income Before Tax | -5.75M | -26.59M | -5.53M | -6.64M | -6.16M |
| Income Tax Expenses | 11.00K | 12.00K | 3.00K | 4.00K | -4.00K |
| Earnings from Continuing Operations | -5.76M | -26.60M | -5.53M | -6.65M | -6.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.76M | -26.60M | -5.53M | -6.65M | -6.15M |
| EBIT | -2.70M | -3.84M | -4.93M | -5.79M | -5.77M |
| EBITDA | -2.68M | -3.80M | -4.89M | -5.75M | -5.74M |
| EPS Basic | -0.15 | -4.92 | -1.02 | -1.23 | -1.14 |
| Normalized Basic EPS | -0.11 | -0.66 | -0.65 | -0.77 | -0.71 |
| EPS Diluted | -0.15 | -4.92 | -1.02 | -1.23 | -1.14 |
| Normalized Diluted EPS | -0.11 | -0.66 | -0.65 | -0.77 | -0.71 |
| Average Basic Shares Outstanding | 38.36M | 5.41M | 5.41M | 5.41M | 5.41M |
| Average Diluted Shares Outstanding | 38.36M | 5.41M | 5.41M | 5.41M | 5.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 0.00% | -0.14% | -- | -0.13% |